Pega-One

Executive Summary

Pega-One is a private French biotech company focused on developing next-generation antibodies for oncology. Its lead asset, imgatuzumab, is a second-generation anti-EGFR monoclonal antibody licensed from Roche. The antibody leverages Glycart's glycoengineering technology to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), potentially improving tumor killing compared to first-generation anti-EGFR antibodies. Imgatuzumab targets EGFR, a well-validated receptor overexpressed in many solid tumors, including colorectal and head and neck cancers. Pega-One aims to address the limitations of existing anti-EGFR therapies, such as resistance and limited immune engagement, by boosting innate immune effector functions. The company's strategy involves advancing imgatuzumab through clinical development and potentially partnering with larger pharmaceutical companies for late-stage trials and commercialization. While still in early stages, Pega-One's differentiated approach could position it competitively in the crowded EGFR space, though significant execution and regulatory risks remain.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 clinical trial for imgatuzumab in EGFR-positive solid tumors60% success
• Q2 2027Announcement of partnership or licensing deal with a major pharma company50% success
• Q1 2027Interim efficacy data from ongoing Phase 1/2 study55% success